Zechendorf Elisabeth, Beckers Christian, Frank Nadine, Kraemer Sandra, Neu Carolina, Breuer Thomas, Dreher Michael, Dahl Edgar, Marx Gernot, Martin Lukas, Simon Tim-Philipp
Department of Intensive Care and Intermediate Care, University Hospital RWTH Aachen, 52074 Aachen, Germany.
Department of Pneumology and Intensive Care Medicine, University Hospital RWTH Aachen, 52074 Aachen, Germany.
Int J Mol Sci. 2023 Aug 4;24(15):12428. doi: 10.3390/ijms241512428.
The COVID-19 pandemic caused by the new SARS-CoV-2 coronavirus is the most recent and well-known outbreak of a coronavirus. RNase 1 is a small endogenous antimicrobial polypeptide that possesses antiviral activity against viral diseases. In this study, we investigated a potential association between ribonuclease 1 and the outcome in COVID-19 patients and the impact of increased and decreased RNase 1 levels serum during the course of the disease. Therefore, two patient populations, Cohort A ( = 35) and B ( = 80), were subclassified into two groups, in which the RNase 1 concentration increased or decreased from time point one to time point two. We show that the RNase 1 serum levels significantly increased in the increasing group of both cohorts ( = 0.0171; < 0.0001). We detect that patients in the increasing group who died had significantly higher RNase 1 serum levels at both time points in Cohort A ( = 0.0170; = 0.0393) and Cohort B ( = 0.0253; = 0.0034) than patients who survived. Additionally, we measured a significant correlation of RNase 1 serum levels with serum creatinine as well as creatinine clearance in the increasing and decreasing group at both time points of Cohort A. Based on these results, there is now good evidence that RNase 1 may play a role in renal dysfunction associated with ICU COVID-19 patients and that increasing RNase 1 serum level may be a potential biomarker to predict outcome in COVID-19 patients.
由新型严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引起的2019冠状病毒病（COVID-19）大流行是最近且最为人所知的冠状病毒爆发事件。核糖核酸酶1（RNase 1）是一种具有抗病毒活性的小型内源性抗菌多肽。在本研究中，我们调查了核糖核酸酶1与COVID-19患者预后之间的潜在关联，以及疾病过程中血清RNase 1水平升高和降低的影响。因此，将两组患者群体，队列A（n = 35）和队列B（n = 80），再细分为两组，其中RNase 1浓度从时间点1到时间点2有所增加或降低。我们发现，在两个队列的升高组中，RNase 1血清水平均显著升高（队列A，P = 0.0171；队列B，P < 0.0001）。我们检测到，在队列A（P = 0.0170；P = 0.0393）和队列B（P = 0.0253；P = 0.0034）中，死亡的升高组患者在两个时间点的RNase 1血清水平均显著高于存活患者。此外，在队列A的两个时间点，我们在升高组和降低组中均测量到RNase 1血清水平与血清肌酐以及肌酐清除率之间存在显著相关性。基于这些结果，现在有充分证据表明，RNase 1可能在与COVID-19重症监护病房患者相关的肾功能障碍中起作用，并且血清RNase 1水平升高可能是预测COVID-19患者预后的潜在生物标志物。
